Adjusted EBITDA margin is being recast from approximately 3% to approximately negative 5% of sales for the full year, which has been updated to include a negative 8 percentage point impact for an acquired in-process research and development charge that occurred in the first quarter of 2025. “We expect to reach $1 billion in worldwide 2025 sales, which is a significant milestone for our company,” said Leigh Vosseller, executive vice president and chief financial officer. “Our narrowed guidance reflects insights gained in the first half of the year, including our U.S. growth expectations as we progress our commercial transformation, increased benefit from accelerated pharmacy channel initiatives and greater contributions from international sales.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Notable companies reporting after market close
- Tandem Diabetes price target lowered to $38 from $48 at Leerink
- Tandem Diabetes downgraded to Sell from Neutral at Citi
- Wells says CBP proposal for CGMs expected, insulin pumps inclusion ‘a surprise’
- Diabetes device maker shares slide after payment scheduling proposal